Application of branched chain amino acid restrictive diet in preparation of medicine for treating tumor liver metastasis

By using a branched-chain amino acid-restricted diet and the SCD1 inhibitor A939572, SREBP1 propionylation modification was reduced, SCD1 expression was downregulated, and lipid synthesis was decreased, thus solving an effective treatment strategy for pancreatic cancer liver metastases. This significantly inhibited the growth and number of liver metastases and provided new dietary interventions and drug targets.

CN122297558APending Publication Date: 2026-06-30AFFILIATED HOSPITAL OF JIANGSU UNIV
1 Cites 0 Cited by

Patent Information

Application Number
CN202610696224.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-05-20
Publication Date
2026-06-30

AI Technical Summary

Technical Problem

In the current technology, there are insufficient treatment strategies for pancreatic cancer liver metastases, especially the lack of effective intervention methods for pancreatic cancer liver metastases, and the effect of existing branched-chain amino acid diets on advanced pancreatic cancer liver metastases is unclear.

Method used

By employing a branched-chain amino acid (BCAA) restricted diet and the SCD1 inhibitor A939572, the expression of SCD1 was downregulated by reducing SREBP1 propionylation modification, thereby reducing fatty acid synthesis and inhibiting the growth of tumor liver metastases. The BCAA restricted diet included a low-BCAA composition, and the drinking water contained specific concentrations of valine, isoleucine, and leucine. The SCD1 inhibitor A939572 exerted its anti-tumor effect by reducing lipid synthesis.

Benefits of technology

It significantly inhibits the growth and number of pancreatic cancer liver metastases, provides new dietary intervention strategies and drug targets, effectively reduces the number and size of liver metastases, and offers new treatment options.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The invention discloses an application of branched-chain amino acid restrictive diet in preparation of a medicine for treating tumor hepatic metastasis, according to mouse model experiments, it is found that by limiting intake of branched-chain amino acids (valine, isoleucine and leucine) in diet or using an SCD1 inhibitor A939572, tumor hepatic metastasis, especially pancreatic cancer hepatic metastasis, can be remarkably inhibited. Experimental results show that the branched chain amino acid restrictive diet or the SCD1 inhibitor can reduce the number and the volume of liver metastases and inhibit growth of the metastases. The invention further discloses an action mechanism of the SREBP1, and the action mechanism is as follows: the transcriptional expression of a target gene SCD1 of the SREBP1 is reduced by reducing propionylation modification of the SREBP1 through branched chain amino acid limitation, so that lipid synthesis is reduced, and an anti-tumor hepatic metastasis effect is achieved. The invention provides a new diet intervention strategy and a new drug target for treating tumor liver metastasis.
Need to check novelty before this filing date? Find Prior Art